The IL-6 pathway has been further validated in recent pivotal studies as a key target for inhibition in inflammatory macular edema 44 Clear anatomical improvement is seen with anti-IL-6 monotherapy Visual acuity gains correlating with the anatomical improvement are observed Vami kibart Phase 3 Program Change from Baseline in BCVA Vamikibart Phase 3 Program Change from Baseline in OCT CST MEERKAT MEERKAT SANDCAT SANDCAT Khurana, et al. Efficacy and Safety of Vamikibart in Patients With Uveitic Macular Edema: First Report of Phase 3 MEERKAT and SANDCAT. Presented at the American Academy of Ophthalmology Retina Subspecialty Day, Orlando, FL, October 17, 2025.